LISATA THERAPEUTICS, INC. 8-K

What Happened

• Lisata Therapeutics, Inc. (formerly Cend Therapeutics) announced in an 8‑K filed Jan 27, 2026 that it and Qilu Pharmaceutical Co., Ltd. entered into a Mutual Termination Agreement terminating their Exclusive License and Collaboration Agreement for certepetide (formerly CEND-1), effective January 23, 2026.
• The original License and Collaboration Agreement dated February 11, 2021 (amended April 26, 2021 and by a side letter on November 10, 2023) covered research, development and commercialization of certepetide in the Greater China territory.

Key Details

• Termination effective date: January 23, 2026; 8‑K filed January 27, 2026 and signed by CEO David J. Mazzo, PhD.
• Territory covered by the original agreement: Greater China (Mainland China, Hong Kong, Macau, Taiwan).
• Previously available consideration from Qilu under the agreement: up to $200 million in development and commercial milestone payments and royalties of 10%–15% on licensed product sales.
• The termination does not relieve either party of obligations that accrued before termination; certain contractual provisions are expressly stated to survive termination.

Why It Matters

• For investors, this formally ends Lisata’s licensed commercialization pathway in Greater China with Qilu, eliminating the previously disclosed potential for up to $200M in milestone payments and any future royalty stream from Qilu under that agreement.
• The filing confirms only the contract termination and survival of prior obligations; it does not disclose replacement arrangements, new partners, or changes to Lisata’s financial projections. Investors should monitor future disclosures for any new licensing deals, partnerships, or guidance on potential revenue impact.